As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to UK MHRA in 2018 about MHRA consultation on EU exit no-deal legislative proposals – ACRO response to Clinical Trials Section only can be found below.